Foghorn Therapeutics Inc [FHTX] stock is trading at $9.72, up 9.46%. An important factor to consider is whether the stock is rising or falling in short-term value. The FHTX shares have gain 29.08% over the last week, with a monthly amount glided 73.57%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Foghorn Therapeutics Inc [NASDAQ: FHTX] stock has seen the most recent analyst activity on September 03, 2024, when Jefferies initiated its Buy rating and assigned the stock a price target of $18. Previously, Evercore ISI started tracking the stock with Outperform rating on August 19, 2024, and set its price target to $20. On March 28, 2023, BofA Securities initiated with a Buy rating and assigned a price target of $10 on the stock. BMO Capital Markets started tracking the stock assigning a Outperform rating and suggested a price target of $20 on January 05, 2023. H.C. Wainwright initiated its recommendation with a Buy and recommended $25 as its price target on November 22, 2021. Wedbush started tracking with a Outperform rating for this stock on November 17, 2020, and assigned it a price target of $24. In a note dated November 17, 2020, Morgan Stanley initiated an Overweight rating and provided a target price of $24 on this stock.
Foghorn Therapeutics Inc [FHTX] stock has fluctuated between $2.70 and $9.75 over the past year. Currently, Wall Street analysts expect the stock to reach $18 within the next 12 months. Foghorn Therapeutics Inc [NASDAQ: FHTX] shares were valued at $9.72 at the most recent close of the market. An investor can expect a potential return of 85.19% based on the average FHTX price forecast.
Analyzing the FHTX fundamentals
Foghorn Therapeutics Inc [NASDAQ:FHTX] reported sales of 35.19M for the trailing twelve months, which represents a growth of 23.02%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -2.7%, Pretax Profit Margin comes in at -2.38%, and Net Profit Margin reading is -2.46%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is 1.4 and Total Capital is -0.34. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -2.86.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.90 points at the first support level, and at 8.08 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.24, and for the 2nd resistance point, it is at 10.76.
Ratios To Look Out For
For context, Foghorn Therapeutics Inc’s Current Ratio is 5.69. On the other hand, the Quick Ratio is 5.69, and the Cash Ratio is 2.73. Considering the valuation of this stock, the price to sales ratio is 15.28.
Transactions by insiders
Recent insider trading involved Bellon Steven F., Chief Scientific Officer, that happened on Sep 09 ’24 when 20000.0 shares were sold. Officer, STEVEN BELLON completed a deal on Sep 09 ’24 to buy 20000.0 shares. Meanwhile, Chief Strategy/Bus Ops Officer Cavalie Fanny sold 11000.0 shares on Mar 11 ’24.
